Gaurav Kumar, MD
Pulmonary Disease · Portage, INNPI 1225219462
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $72,900 of the $102,060 with a category attached, or 71.4%. AstraZeneca accounts for 80.9% of it on its own, with 59 other manufacturers making up the rest. Among pulmonary disease clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 914 payments — averaging $111.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$83K
- Johnson & Johnson$2K
- Boehringer Ingelheim$1K
- Bayer$1K
- Actelion Pharmaceuticals US, Inc.$1K
- Novo Nordisk$1K
- plus $12K from 54 others
What the payments were for
- Speaking & faculty fees$72,90071%
- Travel & lodging$6,1486%
- Food & beverage$22,28022%
- Education$7321%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$76,793
- BREZTRI AEROSPHERE$2,450
- XARELTO$902
- Velphoro$500
- Kerendia$391
- RAYOS$375
- ZEPHYR ENDOBRONCHIAL VALVE$351
- PULMONX CHARTIS TABLET CONSOLE$351
- CHARTIS CATHETER$351
- ZEPHYR DELIVERY CATHETER$351
- Proclaim Family of SCS IPGs$300
- Adempas$266
- UPTRAVI$250
- OPSUMIT$250
- Spin$226
- REMODULIN$138
- ORENITRAM$138
- TYVASO$138
- Monarch Platform$131
- NEXLIZET$125
How this compares
$102,060 in reported general payments places this provider in the 95th percentile of 258 pulmonary disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 26 | $615,616 |
| AdempasRiociguat | 32 | $442,746 |
| Dupixent PenDupilumab | 101 | $384,150 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 267 | $310,059 |
| UptraviSelexipag | 12 | $279,083 |
| OfevNintedanib Esylate | 17 | $220,673 |
| WinrevairSotatercept-Csrk | 13 | $180,137 |
| OpsumitMacitentan | 12 | $152,909 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 116 | $106,831 |
| FarxigaDapagliflozin Propanediol | 52 | $80,559 |
| NucalaMepolizumab | 13 | $61,037 |
| JardianceEmpagliflozin | 43 | $60,162 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $46,994 |
| Breo ElliptaFluticasone/Vilanterol | 68 | $46,428 |
| RybelsusSemaglutide | 30 | $45,641 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $933 | $489,986456 claims |
| BayerAdempas | $1,274 | $442,74632 claims |
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $1,099 | $431,99324 claims |
| Boehringer IngelheimOfev, Jardiance, Stiolto Respimat, Spiriva Respimat, Glyxambi | $1,438 | $355,101148 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Bevespi Aerosphere, Symbicort | $82,555 | $212,231216 claims |
| MerckWinrevair, Dulera | $345 | $185,76624 claims |
| Novo NordiskRybelsus, Xultophy 100-3.6 | $1,095 | $86,22141 claims |
| Johnson & JohnsonXarelto | $1,975 | $39,42648 claims |
| PfizerEliquis | $400 | $21,48446 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 258 pulmonary disease providers in Indiana.
Other pulmonary disease in Portage
- David MaresAnderson$1.3M
- David WilsonSeymour$689K
- Giovanni InfusinoCrown Point$526K
- Ajay DeshpandeTerre Haute$304K
- Faisal KhanGreenwood$207K
- Sandeep KukrejaGreenwood$206K
- Raja DevanathanHobart$193K
- Asaad JandaliMunster$161K
- Rajeev MehtaMuncie$88K
- Gary ZalogaIndianapolis$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.